Navigation Links
Anadys in Medical News

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...bott Diagnostics, Achillion Pharmaceuticals, Inc., anadys Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, ...agnostics Rights from Siemens Healthcare II-63 anadys Secures FDA Fast Track Designation for its Lead Dr...cation for Novel Hepatitis C to with FDA II-68 anadys Discontinues ANA975 II-68 Cerus Bags NIH Fundi...

Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering

...e sale of shares of its common stock and warrants. anadys estimates that net proceeds from the offering will... related expenses payable to the placement agent). anadys has entered into subscription agreements with each...er, solicitation or sale is unlawful. About anadys ...

Anadys Pharmaceuticals to Present at the Citi Biotech Day

... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and an update on its ANA598 clinical program in he...l be available through April 15, 2009. About anadys ...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

... SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a clinica...3. For the twelve months ended December 31, 2008, anadys reported a net loss of $32.4 million, compared to ...onal oral non-nucleoside polymerase inhibitor that anadys is developing for the treatment of chronic hepatit...

Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results

... SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...2009, after the U.S. financial markets close. anadys will hold a conference call and webcast to discuss...l be available through March 12, 2009. About anadys ...

Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

... SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and an update on its clinical programs: ANA598 an...e available through February 23, 2009. About anadys ...

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

... SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...nding doses of ANA598 over a period of three days. anadys expects to enroll approximately 30 patients in the...om all three cohorts in the first quarter of 2009. anadys may elect to explore other dose levels of ANA598 a...

Anadys Pharmaceuticals to Present at Bio Investor Forum

... SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and an update on its development programs. The p...ilable through November 13, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...

Isis Reports Financial Results and Highlights for Fiscal year 2007

... as President and Chief Executive Officer of Regulus. Dr. Xanthopoulos is the co-founder and former President and Chief Executive Officer of anadys Pharmaceuticals, Inc. * Peter S. Linsley, Ph.D., was appointed as Chief Scientific Officer of Regulus. Dr. Linsley was Executive Directo...

Anadys Pharmaceuticals to Present at BIO InvestorForum 2007

... SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... Pharmaceuticals, Inc. will present an overview of anadys and an update on its two development-stage product...nd will be archived until October 24, 2007. About anadys ...
Anadys in Medical Technology

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno... standard of care." ANA598 Program Update anadys continues to make progress on all aspects of the A...l sites. 14 Day Healthy Volunteer Study anadys recently completed dosing healthy volunteers in a ...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

... SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno...d in the second cohort (400 mg bid) of the study. anadys expects to report detailed data from multiple coho...h other anti-HCV agents." About ANA598 anadys retains worldwide rights to ANA598, which was full...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...ASLD SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... have the Potential to Overcome Viral Resistance", anadys will present the results of in vitro studies that ... ANA598 in the Chimpanzee Model of HCV Infection", anadys will present data showing that ANA598 exhibits a s...

Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

... SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and its three clinical programs: ANA598 and ANA773...ailable through October 21, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

...LD SAN DIEGO, Sept. 24 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... http://www.aasld.org . ANA598 Program Update anadys is now finalizing preparations to begin a Phase Ib...rts, eight on active treatment and two on placebo. anadys expects to have viral load data from all three coh...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... PDT SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ery-other-day dosing over 28 days in HCV patients. anadys also continues to enroll patients in a separate Ph...elopment of ANA975. Webcast of Conference Call anadys will host a conference call today, July 7, 2008 at...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

...is C SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...cessful completion of the healthy volunteer study, anadys plans to begin a Phase Ib study of ANA598 in HCV-i...nts in February and this study of ANA598 underway, anadys is now focused on achieving important clinical mil...

Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research

... SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) presented a...iple other anti-HCV agents, regardless of class. anadys also presented the pharmacokinetic (PK) profile of...direct antivirals." About ANA598 In June 2007, anadys announced the nomination of ANA598 as a clinical d...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

...vivo SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced p...eatment of chronic HCV infection." In June 2007, anadys announced the nomination of ANA598 as a clinical d...ith hepatitis C virus infection." About Anadys anadys Pharmaceuticals, Inc. is a biopharmaceutical compa...

Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses

...es SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) presented p...redictor of potential clinical utility." In June, anadys announced the nomination of ANA598 as a clinical d...patients with hepatitis C virus infection." About anadys ...
Anadys in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

... SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its clinical programs: ANA598 and ANA773 in he...ll be available through March 2, 2009. About anadys ...
Anadys in Biological Technology

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno... a number of clinical sites in the United States. anadys expects to receive 28-day safety and response (RVR...n-nucleoside inhibitor of the HCV RNA polymerase. anadys has completed three Phase I clinical studies of AN...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biophar...ly. For the six months ended June 30, 2009, anadys reported a net loss of $15.3 million, compared to ...osed Registered Direct Financing. In early June, anadys closed a "registered direct" offering through the ...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

... SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ..., after the U.S. financial markets close. anadys will hold a conference call and webcast on Thursda...available through August 13, 2009. About anadys ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno...ts in ongoing studies in hepatitis C and oncology, anadys intends to manage the ANA773 programs as potential...ge the tremendous effort and commitment of all our anadys colleagues, especially those whose positions have ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biophar...onal oral non-nucleoside polymerase inhibitor that anadys is developing for the treatment of chronic hepatit...Potent Antiviral Activity in HCV. Earlier today, anadys presented antiviral and safety data from all three...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

... SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...2009, after the U.S. financial markets close. anadys will hold a conference call and webcast on Thursda...will be available through May 7, 2009. About anadys ...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

... SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its clinical programs: ANA598 and ANA773 in he...l be available through April 16, 2009. About anadys ...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

... SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno... hepatitis C non-nucleoside polymerase inhibitor. anadys is currently enrolling patients in a Phase Ib stud...tment regimens." About ANA598 anadys recently initiated patient dosing in a Phase Ib st...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

... SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its three clinical programs: ANA598 and ANA77...ailable through December 17, 2008. About anadys ...

Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference

... SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and its three clinical programs: ANA598 and ANA773...ailable through December 4, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...
Other Tags
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health Food Grocers ... , “Our ‘Ask a Nutritionist’ feature on our website is a free service to ... Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food Grocers’ website offers ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... FL (PRWEB) , ... August ... ... most-visited bodybuilding and fitness site and the largest online retailer of nutritional ... Awards. BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show widespread ... percent of respondents said they agreed or strongly agreed that the controversial law ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
Other Contents